HRT Prescribing Trends 2026: What the New U.S. Data Actually Shows

The HRT Index Editorial TeamIndependent women's health research

Published: August 7, 2026Last reviewed: August 7, 2026

Editorial research — not medically reviewed by a clinician. Why this label

Last updated: August 7, 2026 · Last verified: August 7, 2026 · By The HRT Index Editorial Team. Educational research, not medical advice, and not reviewed by a clinician. See our medical review policy. Full disclosure.

Want to turn the data into a next step?

This page explains prescribing trends and FDA label changes; it cannot determine whether HRT is appropriate for you. Use our free path tool to organize questions for a licensed clinician.

Find My HRT Path

HRT prescribing trends in 2026 point one way: up. Hormone therapy use among U.S. women in outpatient care nearly doubled from 1.7% in January 2017 to 3.6% in April 2026. Women aged 45–54 drove the rise, and patches and vaginal products grew fastest. But use remains historically low, and the headline numbers are easy to misread.

Best for / not for you if

This page is for you if you saw a headline saying HRT use doubled — or another saying it is still falling — and you want to know which is true, what changed at the FDA, and what the data means for your next appointment.

This page is not for you if you want to know whether HRT is safe for you specifically. That depends on your history and belongs with a licensed clinician. Start with our HRT benefits and risks guide. If you are standing at a pharmacy counter with a backordered patch, go straight to our Estradiol Patch Shortage Tracker.

The HRT Index is the independent decision resource for online menopause and HRT care — comparing telehealth providers on clinical legitimacy, care quality, medication fit, price transparency, and access, with every claim verified and dated, so women can choose the path that fits their situation before their first consult.

What we actually verified for this page

We did not run a study. We did something most coverage of this story has not done: we went and read the labels.

On August 7, 2026, we re-opened the FDA’s published list of menopausal hormone therapies with updated prescribing information and recorded exactly which products it names. Then we opened current DailyMed records for Premarin tablets, a Sandoz once-weekly estradiol patch, and Divigel. On each record, we checked the label’s own “Revised:” date and the exact boxed-warning heading.

That firsthand audit is in Section 6. It shows a real FDA change rolling out unevenly across products — not a universal overnight rewrite of every HRT label.

Everything else on this page comes from named third-party datasets. We identify the population, denominator, time period, and definition behind each number because that turns out to be the whole story.

The seven shifts, at a glance

If you read nothing else, read this.

The rebound is real. Epic Research found hormone therapy use in U.S. outpatient care rose from 1.7% to 3.6% between January 2017 and April 2026.
It started in 2023, not 2025. Epic’s measure changed modestly through 2022, then accelerated beginning in 2023 — before the FDA’s 2025 labeling action.
Women 45–54 are the engine. Their use rose from about 24 to 68 per 1,000 women in Epic’s analysis.
The patch passed the pill. In Truveta’s estrogen dataset, patch dispensing rose from 6.2 to 19.9 per 1,000 women while oral estrogen fell from 10.4 to 8.6.
Use is still historically low. National survey data fell from 26.9% of postmenopausal women in 1999–2000 to 4.7% in 2017–March 2020. The current rebound starts from that floor.
The boxed-warning change is real but unfinished. The FDA’s published list contained six products when checked August 7, 2026. Premarin tablets and the Sandoz once-weekly estradiol patch still carried the older four-risk boxed-warning headings in the DailyMed labels we opened.
Getting treatment is still hard. In a 2025 conference abstract covering 5,491 women with menopause-related outpatient visits in one academic system, only 17.1% had a pharmacologic treatment associated with the diagnosis in the EHR.

Before you go further

The right online HRT provider isn't the same for every woman — it depends on your symptoms, your age and whether you have a uterus, your medication route preference (patch, pill, gel, or vaginal estrogen), your risk history, your insurance or cash-pay situation, and your state. Some situations belong with an in-person clinician first. Because a general answer can't resolve those for you, use The HRT Index's Find My HRT Path tool to match your situation to the right provider — and to flag when online care isn't the right starting point — before your first consult.

Not sure where you fit in any of this? Find My HRT Path takes about 90 seconds and gives you a personalized care-path match, two backup routes, and a clear flag when online care is not the right starting point. No email is needed to see your result. → Take Find My HRT Path

1. HRT prescribing trends 2026: are they really rising?

Yes. Two large U.S. real-world analyses show hormone therapy prescribing rising through 2026. Epic Research reported outpatient use climbing from 1.7% in January 2017 to 3.6% in April 2026. Truveta reported estrogen-based prescribing rising from 11.5 to 23.5 per 1,000 women between January 2018 and February 2026.

Two different systems. Two different denominators. Same direction.

Epic Research’s July 30, 2026 analysis included 163,348,471 women aged 18–79 with face-to-face U.S. outpatient care. Its measure changed modestly through 2022, then accelerated in 2023 and continued rising through the most recent month reported.

Truveta’s April 9, 2026 estrogen analysis found another 19.1% increase between July 2025 and February 2026. Among women 45–54, the increase over those seven months was 25.7%.

So the shape is not “nothing happened until the FDA changed a label.” It is a slow build that became visible in 2023, followed by a steeper rise in late 2025 and early 2026.

Progesterone moved in the same direction. Truveta’s June 17, 2026 analysis found progesterone-containing prescribing among women 45 and older rose from 3.0 to 12.4 per 1,000 between January 2018 and May 2026 — a 308.7% increase.

That does not prove every estrogen prescription was paired with a progestogen. It does show that the progestogen side of menopause treatment is rising too. For women with a uterus who use systemic estrogen, a clinician generally considers endometrial protection as part of the regimen.

Data note: Epic and Truveta are analyses of real-world clinical or prescription records, not randomized trials. Truveta labels both 2026 analyses preliminary and not peer reviewed. An order is not necessarily a fill; a fill is not adherence; and none of these datasets measured symptom relief.

2. Why do HRT studies seem to contradict each other?

Because they count different things. Published figures can show a 72% increase, a 308.7% increase, and a long-run decline without any of them being false. The population, denominator, definition of “use,” route included, and end date all change the answer. These numbers describe different slices of the same history and should not be blended.

This is the single most useful thing on this page, so we built the comparison in one place.

The HRT Index 2026 source matrix

Source	Who it counts	What counts as use	Period	Headline number	What it proves	What it cannot prove
Epic Research / Cosmos — July 30, 2026	163,348,471 women aged 18–79 with face-to-face U.S. outpatient care	Hormone-therapy prescription activity recorded under the study protocol	Jan 2017–Apr 2026	1.7% → 3.6%	A broad current rebound by age, route, and hormone category	National household prevalence; adherence; outcomes
Epic Research — Nov 2025, updated Feb 2026	24,235,834 women aged 50–65 with an encounter and an active prescription	A broad medication basket including progesterone, progestins, estrogen, estradiol, medroxyprogesterone, dydrogesterone, levonorgestrel, and tibolone	Cohort 2018–2025; headline comparison Q2 2021–Q4 2025	+72% through Q3 2025; +86% through Q4 2025	Broad hormone prescribing rose in this age band	Menopause-specific use; route; whether every drug was prescribed for menopause
Truveta — estrogen — Apr 9, 2026	U.S. women aged 18+ with prescription data	Estrogen-based HRT prescribing in Truveta Data	Jan 2018–Feb 2026	11.5 → 23.5 per 1,000 (+104.8%)	Current estrogen and route trends	National population prevalence; adherence; outcomes; progesterone use
Truveta — progesterone — Jun 17, 2026	Women aged 45+ with prescription data; 598,797 identified	Micronized progesterone and selected synthetic progestins; Depo-Provera and other mainly non-menopause products excluded	Jan 2018–May 2026	3.0 → 12.4 per 1,000 (+308.7%)	Progesterone-containing prescribing rose sharply	Micronized progesterone alone; menopause indication for every prescription; patient-level pairing with estrogen
Mayo Clinic Proceedings — 2026	13,372,648 U.S. women aged 40+ in commercial and Medicare Advantage claims	At least 180 days of filled systemic hormone-therapy prescriptions in a year	2007–2023	4.4% → 1.7%	Sustained systemic use remained very low through 2023	Local vaginal estrogen; anything after 2023; orders that were not filled
JAMA Health Forum / NHANES — 2024	13,048 postmenopausal U.S. women in a nationally representative survey	Menopausal hormone therapy identified through NHANES household prescription-medication data	1999–Mar 2020	26.9% → 4.7%	The long post-2002 collapse and persistent demographic gaps	The 2021–2026 rebound
NHS Business Services Authority — Oct 23, 2025	Identified patients receiving HRT PPC-list drugs dispensed in community primary care in England	Dispensed HRT items on the HRT Prescription Prepayment Certificate drug list	2023/24–2024/25	2.6M → 2.8M patients (+6.4%)	Use also rose in England, with a deprivation gradient	U.S. prevalence; private prescribing; secondary-care use; all possible menopause medicines

The two Truveta analyses are preliminary and not peer reviewed. The NHS series uses a defined HRT PPC drug list and excludes private and secondary-care prescribing, so it is context — not a directly comparable U.S. rate.

Three things this table tells you that no single study can

One: the decline studies and rebound studies are mostly describing different eras. NHANES stops in March 2020. The Mayo claims analysis runs through 2023 and uses a strict 180-day filled-prescription threshold. Epic detects a faster rise beginning in 2023, while Truveta extends into 2026. Read in sequence, the shape is collapse, a long low plateau, then a recent rebound.

Two: watch the denominator before you repeat the number. Truveta reports rates among women with prescription data. Epic’s current analysis is among women seen in outpatient care. NHANES is nationally representative of postmenopausal women. Mayo requires at least 180 days of filled systemic therapy. The figures are not competing answers to one identical question.

Three — and this one is ours: the widely repeated “+72% / +86%” Epic figure comes from a published medication definition that includes levonorgestrel and tibolone, and the analysis did not separate route. Levonorgestrel is used in hormonal IUDs for contraception and heavy bleeding as well as in some menopause contexts. That does not invalidate the analysis. It makes it a broader hormone-prescribing measure than the menopause headline often implies.

The number everyone is misreading

Now the honest part, and it cuts both ways.

“Hormone therapy use nearly doubled” is a true headline. Epic’s rate went from 1.7% to 3.6%. But doubling a small number gives you a slightly less small number. About 96 in 100 women in that outpatient dataset still did not meet the study’s hormone-therapy-use measure in April 2026.

Put that beside the long view. In 1999–2000, 26.9% of postmenopausal U.S. women in NHANES used menopausal hormone therapy. By 2017–March 2020, the figure was 4.7% — an 82% relative decline.

So the rebound is real, and it is nowhere near a restoration.

Why we are telling you this: if you have been sitting with the feeling that everyone else figured this out and you are late, you are not. You are early to a correction, not late to a trend. That is a materially different position to be in, and it is the more accurate one.

3. Which women are driving the increase?

Women aged 45–54 are driving the sharpest increase in both current datasets. Epic found use in this band rose from about 24 to 68 per 1,000 women between January 2017 and April 2026. Truveta recorded 49.0 estrogen prescriptions per 1,000 women aged 45–54 in February 2026, up 184.2% since 2018.

Every age group rose. This one rose hardest.

Age band	Truveta rate, Feb 2026 per 1,000	Change since Jan 2018
18–44	7.2	+118.3%
45–54	49.0	+184.2%
55–64	41.6	+95.3%
65–74	22.1	+54.8%
75+	15.1	+103.9%

Epic’s independent analysis agrees on the shape: women 45–54 nearly tripled, women 35–44 and 55–64 roughly doubled, and the youngest and oldest groups moved less.

The quiet story inside the numbers

For much of the period in Truveta’s data, the 55–64 band had the higher rate. By February 2026, 45–54 had overtaken it.

That is not a small detail. The age distribution is moving younger. It is consistent with more treatment during perimenopause and early postmenopause, but an age band cannot tell us an individual woman’s menopause stage. Some women at 45 are postmenopausal; some at 54 are still having periods.

The FDA’s November 2025 requested labeling language also added a timing consideration for systemic therapy: clinicians should consider initiation for moderate-to-severe vasomotor symptoms in women under 60 or within 10 years of menopause onset. That is a clinical window, not an automatic eligibility rule.

If you are in this age band and have been told to “wait until you are actually in menopause,” the current data show treatment is increasingly happening before age 55. Whether it is right during perimenopause still depends on your symptoms, bleeding pattern, pregnancy possibility, medical history, and clinician assessment. Our perimenopause symptoms checklist helps you organize that conversation.

4. Which forms of HRT are growing fastest?

Patches and vaginal estrogen products are growing fastest. Truveta found patch dispensing rose from 6.2 to 19.9 per 1,000 women between 2018 and February 2026, overtaking oral estrogen. Vaginal cream rose 413.3% from a smaller base. Oral estrogen was the only major route in that analysis to decline over the full period.

Here is the route shift in full.

Route	Jan 2018 per 1,000	Feb 2026 per 1,000	Change since 2018	Jul 2025–Feb 2026
Patch	6.2	19.9	More than tripled	+26.1%
Vaginal cream	2.8	14.3	+413.3%	+15.2%
Vaginal insert or ring	3.1	4.7	+50.0%	+1.9%
Gel, spray, or topical cream	0.5	1.0	+97.2%	+9.5%
Injectable	0.1	0.2	+186.3%	−16.2%
Oral	10.4	8.6	−16.5%	−9.0%

Epic’s separate analysis lands in the same place using a different measure: transdermal products rose from 0.33% to 1.17% of women, while vaginal products rose from 0.45% to 1.26%. Both outpaced oral and injectable forms.

Why patches and gels are gaining ground

Estrogen taken by mouth passes through the liver before reaching the rest of the body. Estrogen absorbed through the skin avoids that first-pass hepatic exposure. That pharmacology matters, and The Menopause Society’s hormone-therapy guidance notes that blood-clot risk may be lower with transdermal routes than with oral therapy.

This is not a route ranking. The prescribing datasets show behavior, not the reason behind every choice. Route still depends on your history, symptoms, preference, cost, adhesion or skin issues, other medications, and what you will use consistently. Some women have a sound clinical reason to use an oral product.

The vaginal estrogen surge is a different story entirely

The 413.3% increase is the biggest percentage jump in the route table, and it is not mainly about hot flashes.

Low-dose local vaginal estrogen is used for genitourinary symptoms such as vaginal dryness, painful sex, and some urinary symptoms. For patients with genitourinary syndrome of menopause and recurrent UTIs, the AUA/SUFU/AUGS guideline recommends local low-dose vaginal estrogen to reduce future UTI risk; it does not treat an active UTI. Local vaginal therapy is a different decision from systemic therapy, with different dosing, exposure, and risk discussions. It should never be merged into a systemic-HRT headline without a note.

Estring — a vaginal estradiol ring — is one of the six products on the FDA’s current updated-label list. If this is your symptom set, start with our vaginal estrogen versus systemic estrogen guide rather than assuming the systemic pages answer the same question.

One more thing hiding in this data

Epic found progestin-only and estrogen-only categories drove most of the growth, while combined estrogen-plus-progestin products stayed relatively flat. Truveta separately found progesterone-containing prescribing rose 308.7%.

Read together, that pattern is consistent with more route-flexible regimens — for example, transdermal estrogen paired with a separately prescribed progestogen. But neither dataset links the prescriptions at the patient level, so it cannot prove how often women received that exact two-prescription regimen.

That distinction matters. The modern route question may involve two decisions instead of one, but the available trend data cannot tell us the final regimen for each patient.

Epic also reported androgen/testosterone categories were relatively flat. Testosterone remains a prescription Schedule III controlled substance in the United States; none of these trend figures changes the prescription or controlled-substance requirements.

5. Did the FDA labeling change cause the increase?

No — not as the main cause. Epic’s curve begins accelerating in 2023, roughly two years before the FDA requested labeling changes in November 2025. The FDA action overlaps with a further rise in late 2025 and early 2026, but the datasets do not establish causation and the timing rules out the label change as the origin of the trend.

Here is the actual sequence.

Date	What happened
Through 2022	Epic’s measure changes modestly from its 2017 starting point
2023 onward	The rate begins accelerating
July 17, 2025	FDA convenes an expert panel on menopause and hormone therapy
November 10, 2025	FDA requests labeling changes for menopausal hormone-therapy products
February 12, 2026	FDA announces approval of changes for the first six products on its published list
August 7, 2026	The FDA public list still names those same six products

Two years of growth happened before the first FDA regulatory date. Whatever drove 2023 and 2024 was already moving.

The datasets do not identify causes. Plausible contributors include evolving interpretation of the Women’s Health Initiative by age and time since menopause, broader public discussion of menopause, more clinician education, and the growth of virtual menopause care. The FDA action may have reinforced the later rise, but these data cannot assign a percentage of the increase to any one factor.

The label change is best understood as removing a brake, not pressing the accelerator.

What the FDA requested removed — and kept

The requested changes were specific.

Removed from the boxed warning: cardiovascular-disease, breast-cancer, and probable-dementia statements, along with the boxed instruction to use the lowest effective dose for the shortest duration.

Kept in the box: the endometrial-cancer warning for systemic estrogen-alone products.

Kept elsewhere in labeling: cardiovascular and breast-cancer risk information. The FDA requested removal of probable-dementia language from labeling as a whole, but the other risk information did not simply vanish.

Added for systemic therapy: language to consider initiation for moderate-to-severe vasomotor symptoms in women under 60 or within 10 years of menopause onset.

That last line is worth taking into an appointment. It does not say every woman in that window should use HRT. It says timing belongs in the benefit-risk decision instead of being treated as irrelevant.

6. Which HRT products actually had their labels updated?

As of August 7, 2026, the FDA’s published updated-label list contains six products: Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva. The agency said 29 companies submitted proposed changes, so the published list represents an initial batch. Our DailyMed audit also found widely used products whose current labels still carry the older boxed-warning headings.

This is the section we built the page around, because it is the part headlines flatten.

The six on the FDA’s published list

Category	Products
Progestogen alone	Prometrium
Systemic estrogen alone	Divigel, Cenestin, Enjuvia
Topical vaginal estrogen	Estring
Systemic estrogen plus progestogen	Bijuva

We re-opened the FDA page on August 7, 2026. It still listed those six products. That was 176 days after the first-batch announcement on February 12.

The Boxed Warning Ledger

Then we opened the labels themselves. This is what those product records said when checked.

Product	DailyMed record updated	Label “Revised:”	Boxed-warning heading on the current label	Verified
Premarin tablets	June 4, 2026	4/2025	Endometrial cancer, cardiovascular disorders, breast cancer, and probable dementia	Aug 7, 2026
Estradiol transdermal system, once weekly — Sandoz authorized generic	March 4, 2026	12/2023	Endometrial cancer, cardiovascular disorders, probable dementia, and breast cancer	Aug 7, 2026
Divigel	February 27, 2026	2/2026	Endometrial cancer with unopposed estrogen in women with a uterus	Aug 7, 2026

Read that table twice.

Premarin tablets — one of the best-known menopause brands — still carried the older four-risk boxed-warning heading. So did the Sandoz once-weekly estradiol patch we checked. Divigel showed the revised endometrial-only box.

This is why “the FDA removed the HRT black box warning” is too broad. The policy change is real. The label rollout is product-specific.

The trap that makes this hard to verify yourself

A DailyMed record’s “Updated” date is not necessarily the label’s revision date. Routine record maintenance can change the page date without changing the prescribing-information revision.

Premarin’s DailyMed page said “Updated June 4, 2026,” but the label inside said “Revised: 4/2025,” and the older warning heading remained. The Sandoz patch record was updated in March 2026 while the label itself still said “Revised: 12/2023.”

So when you look up your own product: find the “Revised:” line and read the boxed-warning heading. Do not rely on the record-update date alone.

What this actually means for you

The removal is real. It is also rolling, product by product, and unfinished.

Do not assume your prescription’s label changed. Do not assume it did not.

And this part matters: the medication in the package did not physically change on February 12, 2026. The FDA changed which risk statements sit in the box, which remain elsewhere in labeling, and how timing is described. An unchanged label is not a new safety finding. An updated label is not a declaration that the product is appropriate for everyone.

Check your own prescription
Our live FDA HRT Label Change Tracker lists the FDA’s published products, current revision dates, and the wording change by product category. Every table carries a verification date. → Open the current tracker

Then figure out what to do with it. If this changes how you are thinking about starting, switching, or asking about route, Find My HRT Path maps your symptoms, risk flags, state, and payment path — and tells you when online care is not the right starting point. → See which care path fits your situation

7. Did the medical societies change their guidance too?

Mostly, no. The FDA changed how risk is presented in product labeling. ACOG said the November 2025 announcement did not change its guidance to counsel patients according to individual risk factors and treatment goals. The Menopause Society supported removing the warning from low-dose vaginal estrogen while emphasizing individualized review for systemic therapy.

Four organizations, four positions, and they are not identical.

Organization	What its public statement said	Date
FDA / HHS	Requested removal of cardiovascular, breast-cancer, and probable-dementia statements from the boxed warning; retained the endometrial warning for systemic estrogen alone	Nov 10, 2025; first six approved Feb 12, 2026
The Menopause Society	Supported removing the warning from low-dose vaginal estrogen and said systemic estrogen still carries potential risks for some individuals that require detailed review	Nov 10, 2025
ACOG	Said the announcement did not change its guidance to counsel patients based on individual risk factors and treatment goals; also distinguished systemic from low-dose vaginal therapy	Nov 10, 2025
Society of Gynecologic Oncology	Highlighted that the FDA was not removing the endometrial-cancer warning from systemic estrogen-alone products	Nov 20, 2025

The sentence to take into your appointment

The drugs did not change overnight. The framing changed.

That means you do not need to walk in arguing that HRT is now risk-free. It is not. The stronger question is narrower and much harder to dismiss:

Which risks apply to me, at my age and time since menopause, with the route and product I am asking about?

That question can produce a useful answer. “Is HRT safe?” usually produces a slogan.

Where genuine disagreement remains

We are not going to report unanimity that does not exist.

Personal breast-cancer history, tumor biology, thrombotic risk, unexplained bleeding, liver disease, age at initiation, and time since menopause can all change the conversation. The endometrial warning remains for systemic estrogen-alone therapy in women with a uterus. Some clinicians also questioned the pace and process of the federal labeling shift.

If you are weighing personal risk, move to our HRT benefits and risks guide rather than using prescribing volume as a substitute for a clinical assessment.

8. If prescribing is up, why is it still so hard to get treatment?

Because showing up does not guarantee treatment. In a 2025 Menopause Society conference abstract, 5,491 women aged 40–55 had menopause-related outpatient encounters in one academic health system from 2016 through 2023. Only 17.1% had a pharmacologic treatment associated with the menopause diagnosis in the EHR, and specialty strongly influenced what was prescribed.

That number deserves to sit on its own for a second.

Roughly five out of six women in that cohort did not have a pharmacologic treatment tied to the menopause diagnosis in the record.

Among the 17.1% who did, 34% received systemic estrogen, 47% vaginal estrogen, and 16% an SSRI. This was a conference abstract of a retrospective cohort, not a peer-reviewed national study, and the treatment-identification method depended on EHR coding. It still exposes the gap that “HRT is booming” headlines leave out.

Who you see changes what you get

Specialty seen	Share of visits	Pattern reported in the abstract
OB/GYN	64.4%	Most likely to prescribe systemic estrogen
Internal Medicine	17.6%	More likely to prescribe an SSRI
Family Medicine	12.4%	More likely to prescribe an SSRI
Endocrinology	4.5%	Less likely to prescribe hormone therapy

The authors connected this variation to gaps in standardized menopause education across specialties. That is not proof that every refusal is wrong. Some women have a clear contraindication or need a different treatment.

Why this section exists

Because if you have already been turned down, hedged at, or handed an antidepressant without a clear explanation after asking about hormones — you were not imagining the broader inconsistency.

But the next move is not to assume the clinician was untrained or that a prescription is automatically appropriate. Ask what specific risk factor, diagnosis, guideline, or missing information drove the answer. If the explanation is vague, a second opinion from a clinician who routinely treats menopause is reasonable.

A “no” without a case-specific explanation is not a universal verdict on your eligibility.

If you have already been turned away once, do not start from scratch. Find My HRT Path organizes the route, therapy class, payment path, and questions that fit your situation — with a clear flag when your history belongs in person first. → Get your care-path match

9. Why can’t some people fill their estradiol patch prescriptions?

Because patch availability is product-specific, and the two national shortage systems do not show the same picture. ASHP listed an active estradiol transdermal-system shortage updated August 5, 2026, covering selected products from Amneal, Noven, Sandoz, Viatris, and Zydus. The FDA shortage database did not list estradiol patches when checked August 7.

Both can be true because the systems use different reporting pathways and thresholds. ASHP gathers and verifies shortage reports from healthcare practitioners, patients, manufacturers, and distributors. FDA’s database is built around manufacturer reporting and the agency’s statutory shortage framework.

The ASHP page also makes one thing clear: there is no single “estradiol patch” inventory status. Some strengths and manufacturers were backordered or on allocation while others were listed as available.

What the current ASHP bulletin actually says

Noven reported increased demand as the reason for its shortage.
Sandoz, Viatris, Zydus, and Amneal did not provide the same published cause for every affected product.
Bayer’s Climara strengths and several Mylan/Viatris, Dotti, and Lyllana products were listed as available.
Several affected products had no firm resupply date; some were released intermittently or placed on allocation.

So “demand caused the entire shortage” is too neat. Increased demand is one documented cause, but the product-level bulletin does not assign one universal explanation to every manufacturer.

The strange part

Truveta looked for a decline in dispensing and did not find one. Patch dispensing continued rising through February 2026 despite pharmacy-level shortage reports.

That does not disprove the shortage. The Truveta authors noted that 30- or 90-day fills can delay the signal, patients may switch manufacturers, and some patients search multiple pharmacies before finding stock. The national dispensing curve and the pharmacy-counter experience can diverge for months.

What to do if your patch is out

Do not change your dose, cut, ration, or reuse a patch on your own. Product designs differ, and changing the schedule can change delivery.
Call ahead and name the manufacturer, strength, and once- or twice-weekly schedule. Availability is product-specific.
Ask the pharmacist whether another manufacturer of the same prescribed strength and schedule is available. Then confirm any substitution with your prescriber or pharmacist.
Ask your prescriber about another appropriate strength, schedule, or route rather than assuming every patch or every non-patch option is available.

→ Open the Estradiol Patch Shortage Tracker for current manufacturer-and-strength details reconciled against ASHP and FDA.

10. Who is still being left out?

The prescribing rebound is real, and it is not evenly shared. National U.S. survey data show lower menopausal hormone-therapy use among Hispanic and non-Hispanic Black women than non-Hispanic White women across two decades. England’s latest official release also found more than twice as many identified HRT patients in the least-deprived areas as in the most-deprived areas.

Two countries. Two health systems. Same warning: a national average can hide who never reaches care.

The JAMA Health Forum analysis covered 13,048 postmenopausal women across ten NHANES cycles. In 1999–2000, weighted prevalence was 13.8% among Hispanic women, 11.9% among non-Hispanic Black women, and 31.4% among non-Hispanic White women. By 2017–March 2020, the figures were 2.6%, 0.5%, and 5.8%, respectively.

Use fell in every group. The gaps did not disappear on the way down.

England’s latest official NHSBSA release covers 2024/25. It reported 14.7 million HRT items and an estimated 2.8 million identified patients, up 6.4% from 2.6 million in 2023/24. The least-deprived areas had more than twice as many identified patients receiving HRT prescribing as the most-deprived areas.

The England figures are not directly comparable to U.S. rates: they use a defined HRT PPC drug list, community primary-care dispensing, and exclude private and secondary-care prescribing. They still show how a record national total can coexist with a steep access gradient.

Why this belongs on a page about prescribing trends: a national average that doubles can barely move for some women. If your experience has been “everyone is talking about this and I still cannot get seen,” you may be describing a documented distribution problem, not personal failure.

11. What can prescription data not tell you?

Prescription records show what was ordered or dispensed under a study’s rules. They do not prove the medication was picked up, used as directed, effective, or appropriate for the individual patient. None of the trend datasets on this page measured symptom relief, and none establishes that rising use proves safety or better care.

We would rather say this plainly than hide it in a footnote.

An order is not necessarily a fill. Epic includes clinical prescription activity; it does not mean every order reached a patient’s hands.

A fill is not adherence. A dispensing record cannot tell you whether someone used the medication for a week, a month, or a year.

Adherence is not benefit. None of these analyses measured whether hot flashes, sleep, vaginal symptoms, or quality of life improved.

And popularity is not proof. In 1999–2000, 26.9% of postmenopausal women in NHANES used menopausal hormone therapy. A rising number tells you more clinicians and patients are using treatment. It does not tell you whether the treatment is right for your body.

A few more limits matter:

Some datasets cannot confirm the prescription was for menopause. Estrogen, progesterone, progestins, and levonorgestrel can be prescribed for multiple reasons.
The Truveta analyses are preliminary and not peer reviewed. Their scale is valuable, but the status belongs beside the numbers, not buried.
Compounded preparations may be captured inconsistently. Health-system and pharmacy data can miss or classify custom-compounded prescriptions differently, so the total is uncertain.
Route categories differ between studies. Truveta separates vaginal cream from inserts or rings; Epic reports a broader vaginal category.
The datasets cannot prove patient-level pairing. Rising estrogen-only and progesterone-containing categories do not show how often the same patient received both.
No source on this page measures care quality. More prescribing could reflect better access, overuse, appropriate correction from undertreatment, or some mixture. Volume alone cannot settle that.

12. What do the 2026 HRT trends mean for your next appointment?

The 2026 data does not tell you to take hormone therapy. It changes the questions worth asking. The strongest appointment moves are to ask about timing, route, whether your symptoms need local or systemic treatment, endometrial protection if you have a uterus, and the current label for the exact product and manufacturer being discussed.

Five questions the 2026 data earned you

“Given my age and time since my final menstrual period, how does the current timing guidance apply to me?” The FDA requested language to consider systemic therapy for moderate-to-severe vasomotor symptoms in women under 60 or within 10 years of menopause onset. That is a starting point for individualized assessment, not a guarantee.
“Should we discuss a patch or gel instead of a pill?” In Truveta’s dataset, patch dispensing exceeded oral estrogen by February 2026. There may still be a sound reason to choose oral therapy, but the route deserves an explicit decision.
“Are my symptoms genitourinary, systemic, or both?” Vaginal dryness, painful sex, and urinary symptoms may call for local vaginal therapy, while hot flashes and night sweats generally require a systemic discussion. Some women need both.
“If I have a uterus and use systemic estrogen, what is the endometrial-protection plan?” The FDA retained the boxed endometrial-cancer warning for systemic estrogen-alone products.
“Has the label for this exact product and manufacturer been revised?” The answer now varies by product. Check the FDA HRT Label Change Tracker before the appointment so you are asking about a specific label, not a headline.

One thing to sort out before you book

Not everyone should start online.

Start with an in-person or specialist clinician if you have unexplained vaginal bleeding; a personal history of breast cancer or another hormone-sensitive cancer; a history of deep-vein thrombosis, pulmonary embolism, stroke, heart attack, or a known clotting disorder; active liver disease; or symptoms that require a physical examination, imaging, or urgent evaluation.

That list is not exhaustive. New chest pain, sudden shortness of breath, one-sided weakness, or other emergency symptoms need urgent care — not an online HRT intake.

If none of those apply and you have bothersome hot flashes, night sweats, or genitourinary symptoms with a straightforward history, online menopause care may be a reasonable first place to discuss options. A licensed clinician still decides whether a prescription is appropriate.

FDA-approved and compounded are not the same thing

Worth clearing up, because the 2026 label story only applies to one of them.

FDA-approved products undergo FDA review for safety, effectiveness, quality, manufacturing, and labeling before approval. These are the products with FDA prescribing information and boxed warnings.

Compounded preparations are not FDA-approved. FDA does not verify their safety, effectiveness, or quality before marketing. Compounding can serve a legitimate medical need when an FDA-approved product is not medically appropriate or cannot meet a patient’s needs, but the finished compounded preparation does not acquire FDA-approved status.

Everything on this page about boxed-warning revisions applies to FDA-approved product labels only. A compounded preparation has no FDA-approved label to update. If marketing implies a compounded product is generic, equivalent to an approved drug, uses the “same active ingredient,” or is “clinically proven” as a compounded product, slow down.

For the full distinction, use our FDA-approved versus compounded HRT provider guide.

Which care model fits which situation?

This page is not a provider ranking. It is a late-stage map for the reader who has finished the trend data and now needs a practical starting route. The commercial facts below were rechecked against provider-published pages on August 7, 2026.

Care path	Verified example	Best fit	Insurance and pricing	Labs and medication	Hard stop or check
Insurance-billed virtual menopause specialty care	Midi Health	Women with a participating commercial PPO who want a menopause-focused virtual clinician	In-network with most PPO plans; self-pay $250 initial visit and $150 continued-care visit	Clinician orders testing as needed; Midi says it prescribes FDA-approved hormone products	Cannot treat Medicaid or Medi-Cal patients even as self-pay; Medicare beneficiaries may self-pay but cannot submit Midi-related claims
Cash-pay virtual marketplace or subscription	Sesame Care	Women who want to choose a clinician without insurance billing	Current program price must be confirmed on the live booking page; medication costs are separate	Basic labs are included if the provider orders them, with state exceptions; prescriptions go to the patient’s preferred pharmacy	Provider availability, included labs, and total price vary by location and booking
Fully online consumer program	Hers	Women who want a fully online assessment and ongoing messaging	Confirm the current plan price, insurance position, and renewal terms during intake	Publicly lists estradiol pill or patch, progesterone pill, and estradiol vaginal cream as possible prescription options when appropriate	Not available in all 50 states; prescription products require provider consultation

Provider-published facts verified August 7, 2026. State coverage, network status, clinician availability, prices, medication eligibility, lab inclusion, renewal terms, and cancellation terms can change. Confirm the exact total and terms before submitting payment.

One honest limitation before you click

Midi cannot treat Medicaid or Medi-Cal patients, even as self-pay. It is also not covered by Medicare; Medicare beneficiaries may self-pay, but Midi says claims related to its visits, medications, or associated services cannot be submitted.

If Medicaid or Medi-Cal is your coverage, Midi is not your path. If Medicare is your coverage, self-pay is possible but reimbursement is not. Start with HRT cost in 2026 or use Find My HRT Path to see which routes remain.

That hard stop is also why Midi can be a strong fit for the right reader: its model is built around commercial insurance and specialist virtual care, not a universal cash-pay membership. That is exactly what works for many PPO members and exactly what fails for Medicaid patients.

Does one of those models sound like your situation? Compare the full provider data — current price, medication type, insurance, state availability, and limits — in our independent online HRT provider comparison. If you still cannot tell which row is yours, Find My HRT Path will route you before you book.

The HRT Index may earn a commission if you start care through some links on our site, at no added cost to you. Commercial relationships do not change the editorial criteria or verification process. See our affiliate disclosure.

13. What are the organizations closest to this saying?

The primary-source positions are narrower than the headlines. FDA says the first labeling changes are approved and more companies submitted proposals. The Menopause Society supports the low-dose vaginal-estrogen change while retaining individualized systemic-risk review. ACOG says its counseling guidance did not change. ASHP still lists a product-specific patch shortage.

That is the cleanest way to hold the 2026 story without forcing agreement that does not exist.

FDA: The published list currently names six products, while 29 companies submitted proposed labeling changes.
The Menopause Society: The old warning deterred use of low-dose vaginal estrogen; systemic therapy still requires an individual benefit-risk discussion.
ACOG: The label announcement did not erase the need to counsel according to the patient’s own risk factors and treatment goals.
Society of Gynecologic Oncology: The endometrial-cancer warning remains for systemic estrogen-alone therapy.
ASHP: Estradiol patch status is manufacturer-, strength-, and schedule-specific, not one universal shortage state.

No patient testimonial can prove a prescribing trend, a label status, or a medication’s safety. That is why this page uses attributable datasets, labels, and organizational statements instead of asking a personal success story to carry a medical claim it cannot support.

14. Is any of this likely to change again?

Yes — especially the product list and shortage table. The FDA relabeling process is unfinished, and ASHP patch availability can change by manufacturer and strength. Provider prices, insurance language, state availability, lab inclusion, and renewal terms can also move. The conclusions stay trustworthy only if the underlying rows keep their dates.

We would rather publish the update schedule than ask you to assume one exists.

What we re-check	Cadence	Verification method
FDA updated-label product list	Monthly	Open FDA’s published list and record every added or removed product
DailyMed boxed-warning heading and “Revised:” date	Monthly for tracked products; quarterly for the wider roster	Open the current label record, not only the page-update date
Epic and Truveta prescribing figures	Quarterly	Check official research pages for updated end dates, definitions, and corrections
Peer-reviewed national trend studies	Quarterly	Search journal databases for new U.S. prevalence or claims analyses
Estradiol patch shortage status	Monthly, and after major bulletin changes	Reconcile ASHP’s product-level bulletin with FDA’s shortage database
ACOG, The Menopause Society, and SGO positions	Quarterly	Check each organization’s official newsroom or guidance pages
Provider pricing, insurance, state availability, labs, renewal, and cancellation terms	Monthly for top providers; quarterly for the full roster	Re-open provider pricing, FAQ, terms, insurance, and intake pages; label anything that still requires checkout confirmation

What would change this page’s conclusions: a new FDA product batch; a materially revised society guideline; a later national prevalence study; Epic or Truveta data showing the curve has flattened or reversed; or a resolved patch shortage across the affected manufacturers and strengths.

When a figure moves, we update the number, its source, and the “Last verified” date. Material corrections belong on our Corrections page; they should not disappear in a silent overwrite.

This is our HRT Index Verification Standard — the documented process by which we review providers: read every published price, separate FDA-approved from compounded, verify state availability and insurance, and re-check on a fixed schedule. Top providers are rechecked monthly; the full roster is rechecked quarterly. The five pillars stay in this order: clinical legitimacy, care quality, medication fit, price transparency, access.

Frequently asked questions

How much have HRT prescriptions increased in 2026?

It depends on what is counted. Epic Research found hormone therapy use among women in U.S. outpatient care rose from 1.7% in January 2017 to 3.6% in April 2026. Truveta found estrogen-based prescribing rose 104.8% between January 2018 and February 2026. Both show a sustained rise from a low base, but their denominators are different.

What percentage of women take HRT?

There is no single current national percentage that makes all datasets comparable. Epic’s outpatient-care measure was 3.6% in April 2026. Truveta reported 23.5 estrogen prescriptions per 1,000 women with prescription data in February 2026. The latest nationally representative postmenopausal NHANES estimate was 4.7% for 2017–March 2020.

Did the FDA remove the black box warning from HRT?

Partly, and product by product. FDA requested removal of cardiovascular, breast-cancer, and probable-dementia statements from boxed warnings in November 2025 and announced approval for the first six products on February 12, 2026. The endometrial-cancer warning remains for systemic estrogen-alone products, and some widely used products still carried the older box when checked August 7.

Which HRT products are on the FDA’s updated-label list?

As of August 7, 2026, the FDA page listed Prometrium, Divigel, Cenestin, Enjuvia, Estring, and Bijuva. That is the FDA’s published list, not proof that every other product label is unchanged forever. Check the exact product and manufacturer.

Which age group has the highest current HRT rate?

In Truveta’s February 2026 estrogen dataset, women aged 45–54 had the highest rate at 49.0 per 1,000. Epic also found the steepest increase in that band, from about 24 to 68 per 1,000 between January 2017 and April 2026. That does not mean every woman in the age band is an appropriate candidate.

Are patches replacing pills for HRT?

Patch dispensing exceeded oral estrogen in Truveta’s February 2026 data: 19.9 versus 8.6 per 1,000 women. Oral estrogen also declined 16.5% from its 2018 rate. That shows a route shift, not the disappearance of pills or proof that a patch is best for every patient.

Why is there an estradiol patch shortage?

There is no single cause published for every affected manufacturer. ASHP’s August 5, 2026 bulletin listed selected estradiol patches from multiple manufacturers as short or constrained. Noven cited increased demand; several other manufacturers did not publish the same reason. Availability varies by manufacturer, strength, and schedule.

Did ACOG change its HRT guidance after the FDA action?

No. ACOG said the November 2025 announcement did not change its guidance to counsel patients based on individual risk factors and treatment goals. The Menopause Society supported removing the warning from low-dose vaginal estrogen while maintaining individualized review for systemic therapy.

Does more prescribing mean HRT is safe?

No. Prescribing volume measures clinician and patient behavior, not safety, appropriateness, or effectiveness. None of the trend datasets on this page measured symptom relief or clinical outcomes. Benefit and risk vary by age, time since menopause, product, route, dose, and personal history.

Am I too old to start HRT now?

Age alone does not answer that question. Current FDA-requested language adds consideration of systemic therapy for moderate-to-severe vasomotor symptoms in women under 60 or within 10 years of menopause onset. Starting later can involve a different benefit-risk balance and needs an individualized clinician assessment.

Is compounded HRT included in these numbers?

Capture is uncertain and likely incomplete. The datasets rely on health-system, prescription, dispensing, survey, or claims records, and compounded preparations may be recorded differently or missed. Compounded drugs are not FDA-approved, and the FDA label changes on this page do not apply to them.

Can my regular doctor prescribe HRT?

A clinician with prescribing authority in your state can prescribe HRT within that clinician’s scope of practice. Whether the clinician recommends it depends on your history, symptoms, training, and the product involved. State scope-of-practice rules and telehealth requirements vary.

Still not sure which HRT program is right for you?

Take our free matching quiz. Find My HRT Path takes about 90 seconds. You will get a best-fit care route, two backup options, and a clear flag if your history means an in-person clinician should be the starting point.

No email is needed to see your result. Nothing is sold or stored in the tool, and a licensed clinician makes all treatment decisions.

Sources

All sources were rechecked August 7, 2026 unless a different verification date is shown.

Prescribing and utilization

Regulatory and labeling

Clinical societies

Supply

Provider facts

The HRT Index is not a clinic and does not prescribe medication. This page is editorial research and has not been reviewed by a clinician. Nothing here is medical advice, a diagnosis, or a substitute for care from a licensed professional. See our medical review policy, editorial standards, and consumer health data privacy policy.

Ready to make the data personal?

The free Find My HRT Path tool can help you compare possible care routes and flag situations that belong with in-person care first.

Keep reading: